From our February 2020 Newsletter

WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance

Significant advances to the diagnosis of tuberculosis (TB) and drug resistance in adults, adolescents and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO) in a rapid communication released today.

From our January 2020 Newsletter

WHO announces updated definitions of extensively drug-resistant tuberculosis
The definition of extensively drug-resistant tuberculosis (XDR-TB) has been revised by the World Health Organization (WHO)’s Global TB Programme, who have also defined pre-XDR-TB for the first time, highlighting the seriousness of these forms of TB.

Peruvian scientists develop rapid diagnostic kit for tuberculosis
In order to solve one of the most recurrent health problems in Peru, a team of national scientists has been developing a kit for rapid diagnosis of tuberculosis, as well as of its resistance to various drugs, using the Microscopic Observation Drug Susceptibility (MODS) test.

From our December 2020 Newsletter

Overcoming Pediatric Drug-Resistant TB Crisis
Special message from Dr. Tereza Kasaeva, Director of WHO's Global TB Program, on the occasion of World Children's Day and World Antimicrobial Awareness Week.

From our November 2020 Newsletter

TAG's 2020 Pipeline Report: TB chapters released
TAG released newly available TB chapters of its 2020 Pipeline Report. This annual publication reviews progress in research and development for TB diagnostic, preventive, and treatment innovations.

‘Urgent investment required’ to get TB efforts back on track, group says
The group found that TB-related targets established in 2018 during a high-level meeting of the United Nations General Assembly are not on track to be met by 2022, and that COVID-19 has rolled back efforts in some cases.

From our October 2020 Newsletter

Landmark TB Trial Identifies Shorter-Course Treatment Regimen
Results from an international, randomized, controlled clinical trial indicate that a four-month daily treatment regimen containing high-dose, or “optimized,” rifapentine with moxifloxacin is as safe and effective as the existing standard six-month daily regimen at curing drug-susceptible tuberculosis (TB)